Genzyme in India

Genzyme is committed to bringing transformative therapies for patients with rare and special unmet medical needs in India, providing hope where there was none before. More>

December 8, 2016: Sanofi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA Read More>

November 17, 2016: Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis Read More>

November 16, 2016: Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting Read More>

October 28, 2016: Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis Read More>


Genzyme India 15 year anniversary